Kolexia
Vely Frédéric Pharmacien
Vely Frédéric
Pharmacien
Hôpital La Conception
Marseille, France
77 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Inflammation Sepsie Maladie associée aux immunoglobulines G4 COVID-19 Lymphopénie Choc septique Choc Infections à cytomégalovirus Déficits immunitaires

Collaborateurs

Voir plus
Farnarier-Seidel Catherine
Farnarier-Seidel Catherine
Hôpital La Conception, Marseille, France
Schleinitz Nicolas
Schleinitz Nicolas
Hôpital La Timone, Marseille, France
Ebbo Mikael
Ebbo Mikael
Hôpital La Timone, Marseille, France
Grados Aurelie
Grados Aurelie
Centre Hospitalier de Niort, Niort, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88 and CXCR4 mutations and underlying haemopathy.
Journal of neurology   18 novembre 2023
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
Neurology(R) neuroimmunology & neuroinflammation   21 août 2023
CriSIs: Role of Innate Lymphoid Cells in the Immunosuppression of Septic Shock
Essai Clinique (Assistance publique - Hôpitaux de Marseille)   09 août 2023
3MO Comprehensive biomarkers (BMS) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: A subgroup analysis of the precision immuno-oncology for advanced non-small cell lung cancer (pioneer) trial
Abstract Book of the ESMO Immuno-Oncology Congress 2022 7-9 December 2022   01 décembre 2022
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination FORCE).
Critical care medicine   10 octobre 2022
Anti-cytokine autoantibodies: Review of the literature.
La Revue de medecine interne   09 juillet 2022
Correction: Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia.
Cellular & molecular immunology   31 octobre 2021
Late-Onset Progressive Multifocal Leukoencephalopathy (PML) and Lymphoma in a 65-Year-Old Patient with XIAP Deficiency.
Journal of clinical immunology   27 septembre 2021
Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers.
Arthritis & rheumatology (Hoboken, N.J.)   03 septembre 2021
FORCE: A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia
Essai Clinique (Innate Pharma)   26 mai 2021